Chardan Expecting Nearly 50% Downside In Sage Therapeutics, Starts At Sell
May 24, 2016 at 07:03 AM EDT
SAGE Therapeutics Inc (NASDAQ: SAGE) is expected to announce Phase 3 data for its lead candidate SAGE-547 [allopregnanolone] in ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.